AnaptysBio, Inc

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on immunology therapeutics for autoimmune and inflammatory diseases. Its internal pipeline includes rosnilimab for rheumatoid arthritis and ulcerative colitis, ANB033 for celiac disease and eosinophilic esophagitis, and ANB101 for additional immune-mediated indications. The company also monetizes discoveries made through collaborations, including Jemperli (dostarlimab) with GSK and imsidolimab with Vanda Pharmaceuticals. As a result, AnaptysBio combines early-stage drug development with collaboration-based revenue from milestones, royalties, and license services rather than product sales.

20,7 %

−5,6 %

+157,0 %

9.07

— AnaptysBio, Inc
	%
Clinical-stage pipeline therapeutics	0% Internally discovered antibody programs advancing through Phase 1 and Phase 2 trials for autoimmune and inflammatory diseases.
Collaboration revenue	100% Milestone, royalty, and research funding revenue from partnered programs such as GSK and Vanda.
License and transition services	0% Services tied to out-licensed assets and collaboration transition activities, especially under the Vanda agreement.

AnaptysBio does not sell commercial products directly to patients; its current revenue comes primarily from...

Pharmaceutical collaboration partnersprimary
Large biopharma partners such as GSK and Vanda that pay upfront fees, milestones, royalties, and service revenue for licensed antibody assets.
Healthcare providerssecondary
Physicians and treatment centers would prescribe any approved autoimmune or inflammatory disease therapies developed from the pipeline.
Third-party payorssecondary
Commercial insurers and government programs that determine reimbursement and therefore the commercial viability of future products.
Clinical research ecosystemsecondary
CROs, trial sites, and manufacturing vendors that support development and supply for the company’s clinical programs.

AnaptysBio is headquartered in San Diego, California and operates primarily from the United States...

•Headquartered in San Diego, California
•Core research and corporate operations are U.S.-based
•Future commercialization may extend to Europe and other markets
•Collaboration economics include U.S. and EU regulatory milestones
•Single-site concentration increases disaster recovery risk
•No country-level revenue disclosure was provided in the excerpts

AnaptysBio’s strategy is to advance its internal immunology pipeline while monetizing selected discoveries through...

Advance rosnilimab clinical developmentshort-term

Rosnilimab is the lead internal program and the main driver of future standalone value creation.

Expand proof-of-concept for ANB033 and ANB101medium-term

Additional pipeline assets diversify scientific risk and broaden the company’s immunology franchise.

Monetize partnered assets through royalties and milestonesmedium-term

Collaboration economics provide funding and reduce dependence on equity financing.

The company faces the core biotechnology risk that its product candidates may fail in clinical development or be...

critical

Clinical development failure

The company’s value depends on unproven pipeline assets advancing successfully through trials.

Scope: Rosnilimab, ANB033, ANB101
Materiality: high

high

Safety or tolerability issues in trials

Adverse events could reduce the chance of regulatory approval and commercial acceptance.

Scope: All clinical-stage programs
Materiality: high

high

Regulatory approval delays

Biologics cannot generate product revenue until approvals are obtained in the U.S. and abroad.

Scope: U.S. and foreign jurisdictions
Materiality: high

high

Partner dependence

Milestones and royalties rely on collaborators’ development and commercialization performance.

Scope: GSK and Vanda agreements
Materiality: high

medium

Natural disaster and site concentration

San Diego operations face earthquake, wildfire, and power outage risk, with limited recovery redundancy.

Scope: Headquarters and stored antibody sequences/data
Materiality: medium

Collaboration revenue recognition

Can materially change reported revenue timing

Sale of future royalties accounting

Affects operating results and financing-related expense

Clinical trial accruals

Can cause period-to-period expense adjustments

Stock-based compensation

Raises non-cash G&A and R&D expense

AnaptysBio, Inc

Clinical development failure

Safety or tolerability issues in trials

Regulatory approval delays

Partner dependence

Natural disaster and site concentration

ENANTA PHARMACEUTICALS INC

Dianthus Therapeutics, Inc. /DE/

ALUMIS INC.

Inmune Bio, Inc.

INCYTE CORP

Upstream Bio, Inc.